Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler by Kralikova, Eva et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Public Health
Open Access Research article
Smoking cessation or reduction with nicotine replacement therapy: 
a placebo-controlled double blind trial with nicotine gum and 
inhaler
Eva Kralikova*1, Jiri T Kozak2, Thomas Rasmussen3, Gunnar Gustavsson3 and 
Jacques Le Houezec4
Address: 1Institute of Hygiene and Epidemiology, First Faculty of Medicine and the General University Hospital in PragueTobacco Dependence 
Treatment Centre of the 3rd Medical Department - Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University 
in Prague and the General University Hospital, Studnickova 7, 128 00 Prague 2, Czech Republic, 2Hospital Kutna Hora, Vojtesska 26, 284 01 Kutna 
Hora, Czech Republic, 3McNeil AB, Medical Affairs & Clinical Research, McNeil AB, PO Box 941, 251 09 Helsingborg, Sweden and 4Consultant in 
Public Health, Rennes, France, and Special lecturer, University of Nottingham, UK. Amzer-Glas, 176 rue de Brest, 35000 Rennes, France
Email: Eva Kralikova* - eva.kralikova@lf1.cuni.cz; Jiri T Kozak - eva.kralikova@lf1.cuni.cz; Thomas Rasmussen - TRasmuss@its.jnj.com; 
Gunnar Gustavsson - GGustavs@its.jnj.com; Jacques Le Houezec - jacques.lehouezec@amzer-glas.com
* Corresponding author    
Abstract
Background: Even with effective smoking cessation medications, many smokers are unable to
abruptly stop using tobacco. This finding has increased interest in smoking reduction as an interim
step towards complete cessation.
Methods: This multi-center, double-blind placebo-controlled study evaluated the efficacy and
safety of nicotine 4 mg gum or nicotine 10 mg inhaler in helping smokers (N = 314) to reduce or
quit smoking. It included smokers willing to control their smoking, and participants could set
individual goals, to reduce or quit. The study was placebo-controlled, randomized in a ratio of 2:1
(Active:Placebo), and subjects could choose inhaler or gum after randomization. Outcome was
short-term (from Week 6 to Month 4) and long-term (from Month 6 to Month 12) abstinence or
reduction. Abstinence was defined as not a single cigarette smoked and expired CO readings of
<10 ppm. Smoking reduction was defined as a reduction in number of cigarettes per day by 50% or
more versus baseline, verified by a lower-than-baseline CO reading at each visit during the same
periods.
Results: Significantly more smokers managed to quit in the Active group than in the Placebo group.
Sustained abstinence rates at 4 months were 42/209 (20.1%) subjects in the Active group and 9/
105 (8.6%) subjects in the Placebo group (p = 0.009). Sustained abstinence rates at 12 months were
39/209 (18.7%) and 9/105 (8.6%), respectively (p  = 0.019). Smoking reduction did not differ
between the groups, either at short-term or long-term. Twelve-month reduction results were
17.2% vs. 18.1%, respectively. No serious adverse events were reported.
Conclusion: In conclusion, treatment with 10 mg nicotine inhaler or 4 mg nicotine chewing gum
resulted in a significantly higher abstinence rate than placebo. In addition a large number of smokers
managed to reduce their cigarette consumption by more than 50% compared to baseline.
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Background
The efficacy of nicotine replacement therapy (NRT) as an
aid to smoking cessation is well documented [1]. Because
of its efficacy and safety profile, NRT is recommended as
first-line pharmacological treatment for tobacco depend-
ence. However, although most smokers state that they
would like to quit, many are unable to abruptly stop using
tobacco [2]. Some smokers have tried to quit and failed,
so interventions that focus only on abrupt cessation are
unlikely to motivate such smokers to alter their behavior.
Nicotine replacement therapy could also help smokers
who are not able or willing to abruptly quit to reduce their
smoking, by replacing some of the nicotine normally
obtained from cigarettes [3]. Smoking reduction could
represent a first step towards cessation, since in reducing
their cigarette consumption smokers experience a degree
of success in controlling their smoking behavior and this
can encourage subsequent quit attempts [2,4]. Several pre-
vious studies of NRT for smoking reduction in smokers
unable or not ready to stop resulted in about 10% of sub-
jects being smoke-free at 12-24 months [5-8].
The present study investigated the efficacy of NRT to facil-
itate either smoking cessation or a reduction in smoking
by 50% or more during a 6-month treatment period, with
follow-up at 9 and 12 months. Our study differed from
previous trials because smokers could choose one of two
NRT products, gum or inhaler, and were given the oppor-
tunity to quit or reduce. The safety of NRT use, while
smoking, was also investigated.
Methods
Study design
This was a double-blind, placebo-controlled trial with
parallel groups, performed at two medical centers (Prague
and Kutná Hora) in the Czech Republic. Two NRT prod-
ucts were used, nicotine 10 mg inhaler and nicotine 4 mg
gum. The choice of NRT was offered to optimize compli-
ance with treatment to achieve the best possible quit rate
or reduction rate. Smoking cessation was recommended
but not mandatory; subjects who could not achieve or
maintain abstinence were asked to reduce their smoking
as much as possible. The study design is shown in Figure
1.
Study design and success definitions Figure 1
Study design and success definitions.BMC Public Health 2009, 9:433 http://www.biomedcentral.com/1471-2458/9/433
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Subjects
Subjects were recruited via an advertisement in the local
Prague newspaper "Metro" (distributed free on Prague
public transport), and using local leaflets in Kutna Hora.
The ad and leaflet had a standardized content that invited
smokers to participate in a clinical trial to control their
smoking. Both the newspaper ads and the subject infor-
mation put equal emphasis on cessation and reduction.
Respondents were initially screened by telephone; up to
325 eligible smokers were invited to participate in the
study and to come to the personal screening. Eligible sub-
jects were at least 18 years old, smoked ≥ 15 cigarettes per
day (cpd), had smoked regularly for ≥ 3 years, had an
expired air carbon monoxide (CO) level of ≥ 10 parts per
million (ppm), wanted to reduce their smoking, and had
previously made at least one failed quit attempt (i.e., all
participants had experienced difficulties trying to stop on
their own), but did not have to be motivated to quit
smoking. All participants provided informed consent, and
the ethics committee of the First Faculty of Medicine, and
the General University Hospital, Charles University,
Prague, approved the study. Eligible subjects received
brief smoking cessation/reduction support and informa-
tion about the use of NRT.
Exclusion criteria included current use of NRT or other
nicotine-containing products (such as cigars, pipes,
snuff), and current involvement in other smoking cessa-
tion or smoking reduction programs. Unstable angina
pectoris or myocardial infarction within the previous 3
months, pregnancy/lactation or intended pregnancy, psy-
chiatric treatment or medication, and co-existing alcohol
or other drug problems precluded participation.
Procedure
At inclusion and during the study, subjects received brief
(up to 10 minutes) behavioral smoking reduction/cessa-
tion support. Subjects were instructed to reduce their
smoking by replacing as many cigarettes as possible with
treatment, either inhaler (nicotine 10 mg or placebo) or
gum (nicotine 4 mg or placebo), according to their choice.
A randomization ratio of 2:1 (Active:Placebo) was used to
accommodate the need for a control group while, for eth-
ical reasons, allowing most of the population use active
medication. The product selected at randomization (gum
or inhaler) could not later be changed. Commercially
available nicotine inhaler and nicotine gum (Nicorette®,
McNeil AB) were used as the active investigational medi-
cations. The placebo groups received matching treatment
that did not contain nicotine.
The treatment schedule was 6 months of full treatment,
followed by up to 3 months of voluntary tapering to pre-
vent relapse to smoking. Follow-up visits were at 9 and 12
months. The recommended doses were 6-12 cartridges
daily, but not more than 12 cartridges in any 24-hour
period, for the inhaler, and ad libitum use, up to a maxi-
mum of 24 pieces/day, for the gum. Treatment compli-
ance was measured at each visit; subjects reported the
quantity of used medication and returned any unused
medication.
Assessments
Nine clinic visits were scheduled: screening, baseline,
Weeks 2, 6, 12, and Months 4, 6, 9 and 12. Demographic
data, smoking history and nicotine dependence using the
Fagerström Test for Nicotine Dependence (FTND) [9] was
recorded at baseline. Expired CO levels were assessed at
each visit. Intention to quit was measured at all visits from
baseline onwards. Plasma cotinine was measured at base-
line, Week 6, and Months 4, 6 and 12. Regarding safety,
adverse events were assessed at all visits from Week 2
onwards. Cardiovascular biomarkers were also assessed,
but the biomarker results are not presented in this paper.
Smoking consumption was monitored from Week 2 to
Month 12, and use and acceptability of study treatment
were assessed from Week 2 to Month 6 using a standard
questionnaire.
Outcomes
The treatment goal was either complete abstinence or
reduction of ≥ 50% in the number of cpd smoked. Sus-
tained abstinence was defined as not a single cigarette
smoked and expired CO readings <10 ppm at each visit.
Point prevalence abstinence was defined as not a single
cigarette smoked during the previous 7 days and a CO
reading <10 ppm. Smoking reduction was defined as a
reduction in smoking by 50% or more versus baseline,
verified by a lower-than-baseline CO reading at each visit.
As the subjects were free to make quit attempts at any time
during treatment, the standard definition of sustained,
complete abstinence from study start is therefore not ade-
quate. Instead, sustained abstinence and reduction are
reported for an early short-term period (from Week 6 to
Month 4) and a later long-term period (from Month 6 to
Month 12). Subjects who achieved sustained abstinence
were termed Abstainers, and subjects who reduced smok-
ing by ≥ 50% were termed Reducers.
Statistical analysis
The primary analysis was an intention-to-treat analysis,
which included all subjects who received treatment. Drop-
outs were regarded as treatment failures. All statistical tests
were two-tailed and at a 5% significance level. No formal
adjustments for multiplicity were made, but p-values were
presented for each test to allow for relevant interpretation.
The Wilcoxon rank sum test was used to test intra-individ-
ual differences from baseline to 4 and 12 months in each
outcome group. Primary efficacy results were analyzed
using Pearson's Chi-square test. In a separate analysis ofBMC Public Health 2009, 9:433 http://www.biomedcentral.com/1471-2458/9/433
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efficacy using logistic regression, baseline FTND score, CO
level and cigarette consumption were tested as prognostic
factors.
Results from previous studies of cessation/reduction sug-
gested success rates of reducing smoking of 50% in the
Active treatment group and 30% in the Placebo group.
Given these conditions, 140 + 70 = 210 subjects (ratio
2:1) were needed for an alpha of 0.05 and a power of
80%. A total of 325 subjects, well above the number
needed, attended the screening visit.
Results
Study population
Out of the 325 eligible subjects, 314 smokers (131 males,
183 females), recruited between January and May 1999
entered the trial (11 enrolled subjects never attended
baseline). Their mean age was 46 (range 20-68) years,
mean baseline cigarette consumption was 25 cpd (range
13*-70), and mean age at onset of smoking was 18 years
(range 8-42). Mean baseline value for expired CO was 23
ppm (range 1*-58) and the mean FTND score was 6.0
(range 0-10) (Table 1). All participants who fulfilled the
inclusion criteria were randomised at screening visit, but
13 subjects had reduced smoking between the screening
and baseline visits, which explains the low number of cpd,
CO level and FTND score at baseline in some subjects.
Treatment choice and compliance
Two hundred and nine subjects were allocated to Active
NRT, and 105 to Placebo. After randomization subjects
could choose between inhaler and gum within their own
treatment code; 263 subjects chose inhaler (111 males,
152 females), and 51 chose gum (20 males, 31 females).
The inhaler was chosen by 84% of subjects (85% males,
83% females).
In the Active group, 84% of the 196 subjects who attended
the Week 2 visit reported daily use of treatment, compared
to 80% of the 95 subjects in the Placebo group. Corre-
sponding figures at 9 months were 58/130 (45%) and 24/
62 (39%) in the Active and Placebo groups, respectively.
Comparisons of compliance showed that gum users were
more perseverant; 68% in the Active group and 67% in the
Placebo group were still using the product daily at 9
months, vs. 41% and 34%, respectively, in the inhaler
groups. The main reason for not using treatment was "did
not need it" in both groups.
Efficacy
Sustained and point prevalence abstinence rates were sig-
nificantly higher in the Active group than the Placebo
group, both at short-term (from Week 6 to Month 4) and
long-term (from Month 6 to Month 12) follow-up (Table
2; Figure 2). Sustained abstinence rates at 4 months were
20.1% (Active) vs. 8.6% (Placebo; p = 0.009); 12-month
results were 18.7% vs. 8.6%, respectively (p  = 0.019).
Point prevalence abstinence rates were Active 26.3% vs.
Placebo 13.3% at 4 months (p = 0.009), and 21.5% vs.
10.5%, respectively, at 12 months (p = 0.016).
Although a large proportion of subjects reduced their
smoking by more than 50%, there was no statistically sig-
nificant difference between Active and Placebo groups,
either at short-term (Week 6 through Month 4) or long-
term (Month 6 through Month 12) follow-up (Table 2;
Figure 2). At 4 months, 19.6% of the Active group and
23.8% of the Placebo group had successfully reduced
smoking. Twelve-month reduction results were 17.2% vs.
18.1%, respectively.
Figure 3 shows the total number of abstainers, reducers
and failures in the short term and long term. It illustrates
how subjects migrated between outcome classifications;
as these were two separate subgroups, subjects could go
from being, for example, an abstainer in the first phase to
a reducer in the second phase. Eighty percent (41/51) of
the short-term abstainers were also long-term abstainers;
7.6% of short-term reducers and 1% of short-term failures
became abstinent long term. 6.6% of initial failures suc-
ceeded in reducing long-term.
Table 1: Demographic characteristics at baseline. Values are mean ± standard deviation (range)
Characteristic Active NRT
(n = 209)
Placebo
(n = 105)
Gender 89 M/120 F 42 M/63 F
Age (years) 46.1 ± 10.5 (20-68) 46.6 ± 10.0 (20-67)
Age started smoking (years) 18.3 ± 3.3 (8-30) 18.6 ± 3.9 (12-42)
Cigarettes smoked per day 25.7 ± 9.8 (13*-60) 25.2 ± 8.2 (15-70)
Expired CO level (ppm) 22.9 ± 10.0 (1*-58) 23.9 ± 9.0 (9-54)
Total FTND score 5.8 ± 2.1 (0*-10) 6.2 ± 2.1 (1*-10)
Abbreviations: CO = carbon monoxide; ppm = parts per million, FTND = Fagerström Test of Nicotine Dependence
* All participants fulfilling inclusion criteria were randomised at screening visit, but 12 subjects had reduced smoking between screening and baseline 
visit explaining the low number of cpd, CO and FTND at baseline in some subjects.BMC Public Health 2009, 9:433 http://www.biomedcentral.com/1471-2458/9/433
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Prognostic factors
Baseline FTND score, CO level and cigarette consumption
were tested as prognostic factors. In this study, only
expired CO was related to successful smoking reduction
or cessation: a lower baseline CO was associated with
higher success probability, chi-square p = 0.01 and p <
0.05 for 4-month and 12-month reduction or cessation,
respectively.
Intention to quit
Subjects who were still smoking were asked: "Do you
intend to quit smoking completely in the next month?"
Responses were rated from 0 = "definitely not" to 4 = "def-
initely".
At 4 months, neither the 52 Reducers nor 80 Failures who
responded had changed their intention to quit. Reducers
had a mean (SD) score of 2.9 (1.0) at baseline and 3.1
(1.1) at month 4. Failures had scores of 2.8 (1.2) and 2.7
(1.1), respectively. Long-term reducers (N = 52) decreased
their mean score from 3.1 (0.9) at baseline to 2.3 (1.2) at
Month 12 (Wilcoxon p < 0.001), compared to ratings of
2.7 (1.1) versus 2.5 (1.2) (NS) in 81 failures.
Plasma cotinine levels
At 4 months, mean plasma cotinine concentration had
significantly decreased versus baseline in Abstainers (Wil-
coxon; p ≤ 0.001) and Reducers (p =≤ 0.001), but was
unchanged in Failures (Table 3). At 12 months, mean
plasma cotinine was decreased only in Abstainers (p <
0.001).
Expired carbon monoxide
At 4 months, mean expired CO had decreased versus base-
line in Abstainers (Wilcoxon; p < 0.001), and Reducers (p
< 0.001), but was unchanged in Failures (Table 3). At 12
months, mean expired CO had decreased in Abstainers (p
< 0.001), Reducers (p < 0.001), and Failures (p < 0.001).
Although the decrease in CO was statistically significant in
all three groups, the magnitude of decrease was far greater
in Abstainers and Reducers than in Failures.
Adverse events
Concomitant use of 10 mg nicotine inhaler or 4 mg nico-
tine gum with cigarette smoking was well tolerated, and
no unexpected adverse events occurred during the study.
The incidence of adverse events was higher in the Active
group (82 events in 209 subjects) than the Placebo group
(26 events in 105 subjects). Of the 82 events in the Active
group, 47 (57%) were mild, 28 (34%) moderate and 7
(9%) severe. Of the 26 events in the Placebo group, 22
(85%) were mild, 3 (12%) moderate and 1 (4%) severe.
The most common events were throat/mouth irritation
and cough. Signs of possible nicotine-related systemic
events were reported in 6 subjects in the Active group (2
nausea, 3 vertigo, 1 palpitation) compared to 1 in the Pla-
cebo group (vertigo).
Treatment-related adverse events were cough (Active 9 vs.
Placebo 3), heartburn (3 vs. 0), and mouth, throat and
Short title: Sustained reduction and abstinence from week 6  to month 4, and month 6-12 Figure 2
Short title: Sustained reduction and abstinence from 
week 6 to month 4, and month 6-12. Detailed legend: 
Sustained reduction and abstinence from week 6 to month 4, 
and from month 6 to month 12 in active vs. placebo groups 
(see text for definitions and p values).
0
5
10
15
20
25
Sustained reduction
W6-M4
Sustained reduction
M6-M12
Sustained
abstinence W6-M4
Sustained
abstinence M6-M12
%
Active (N=209) Placebo (N=105)
Table 2: Primary efficacy results: smoking cessation and smoking reduction. 
Definition Active (n = 209) Placebo (n = 105) χ2 p-value
n%n %
Sustained abstinence from W6 to M4 42 20.1 9 8.6 0.009
Sustained abstinence from M6 to M12 39 18.7 9 8.6 0.019
Point prevalence abstinence at 4 M 55 26.3 14 13.3 0.009
Point prevalence abstinence at 12 M 45 21.5 11 10.5 0.016
Sustained reduction from W6 to M4 41 19.6 25 23.8
Sustained reduction from M6 to M12 36 17.2 19 18.1
Summary of primary efficacy results: smoking cessation and smoking reduction from week 6 to month 4, and from month 6 to month 12.BMC Public Health 2009, 9:433 http://www.biomedcentral.com/1471-2458/9/433
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tongue irritation (15 vs. 1) with the inhaler, and mouth
and throat irritation (Active 2 vs. Placebo 1), salivation (2
vs. 0), upset stomach and hiccups (3 vs. 0) with the gum.
Discussion
The purpose of this study was to investigate whether
smokers prepared to control their smoking, but not neces-
sarily prepared to quit smoking, could reduce or quit with
a choice of one of two NRT products, nicotine 4 mg gum
or nicotine inhaler. The study also evaluated the safety of
NRT used concomitantly with cigarette smoking.
In the short-term, between Week 6 and Month 4, Active
treatment achieved a significantly higher rate of sustained
abstinence than Placebo (p  ≤ 0.009). In the long-term
(Months 6-12), sustained abstinence was significantly
superior with Active treatment (p ≤ 0.019). Subjects could
choose between two NRT forms, although use of a pre-
ferred form has not been shown to increase outcome [10].
In our study the outcome did not differ between gum and
inhaler users, although another study has suggested that
adherence to inhaler can be quite low [11]. The subjects'
preference for the inhaler (chosen by four-fifths of sub-
jects) over the gum may have been due to the novelty of
the inhaler, which was not available on the Czech market
at the time this study was performed. However, gum users
were more compliant than inhaler users, which may
reflect the novelty of the inhaler; subjects chose the
inhaler because it was new, but found it more difficult to
use than gum. Reasons may be that gum is more discreet
to use in public, and that the inhaler has to be used much
more intensively than a cigarette to obtain an adequate
dose of nicotine [10].
Overall, NRT increases long-term cessation rates by 50 to
70%, irrespective of the formulation, in smokers moti-
vated to quit [1]. Classical smoking cessation trials enroll
subjects motivated to quit, whereas our study recruited
smokers who wanted to 'control their smoking', which
implied either reducing cigarette consumption or imme-
diate quitting. Nonetheless, we observed similar results:
short- and long-term abstinence in the Active group was
approximately double that in the Placebo group. The one-
year abstinence rate in our study (18.7%) was higher than
that observed in a number of previous trials of NRT prod-
ucts for smoking reduction (8-12%) [5-8]. This is not sur-
prising, given the different study populations: our study
invited smokers who wanted to control their smoking (in
any way), whereas previous studies of NRT for smoking
reduction specifically enrolled smokers unable or not
motivated to quit [5-8]. However, the results from our
study confirm earlier findings that offering smoking
reduction does not undermine cessation [4].
Number of subjects in each outcome group between Week  6-Month 4 and Months 6-12 Figure 3
Number of subjects in each outcome group between 
Week 6-Month 4 and Months 6-12. Detailed legend: 
Number of subjects in each outcome group (abstainers, 
reducers, failures) between Week 6-Month 4 and Month 6-
Month 12. The arrows to the left of the column for Month 6-
Month 12 denote the previous status of these subjects during 
Week 6-Month 4.
Wk6 to M4
197
66
51
M6 to M12
48
55
211
41
5
2
3
39
13
7
22
182
Sustained Abstainers  
Reducers
Failures
Table 3: Plasma cotinine and expired carbon monoxide (CO) levels
Cotinine
(ng/ml)
CO (ppm)
Outcome group 4 months 
(baseline)
p 12 months 
(baseline)
p 4 months 
(baseline)
p 12 months 
(baseline)
p
Abstainers* 80 (220) N = 46 <.001 40 (232) N = 45 <.001 4.5 (23.0) N = 51 <.001 2.7 (22.4) N = 48 <.001
Reducers* 184 (279) N = 63 <.001 216 (253) N = 50 NS 13.1 (26.4) N = 66 <.001 11.7 (26.3) N = 55 <.001
Failures 265 (259) N = 73 NS 271 (257) N = 80 NS 20.7 (19.4) N = 88 NS 17.2 (20.4) N = 90 <.001
*Includes all subjects who were classed as Abstainers and Reducers in both the Active and Placebo treatment groups.BMC Public Health 2009, 9:433 http://www.biomedcentral.com/1471-2458/9/433
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The reduction rate was also high in the placebo group. If
smokers could reduce, and sustain that reduction, active
medications might help even more smokers to quit
because they would be starting from a lower level of nico-
tine dependence, if they had already reduced smoking,
either with or without the help of treatment. This hypoth-
esis could be tested in future studies.
The study design included a screening visit 2 weeks before
baseline. Some subjects reduced their cigarette consump-
tion between the screening visit and baseline visit, with
the result that baseline measurements of cigarette smok-
ing, carbon monoxide and FTND did not accurately reflect
smoking levels before the screening visit. This may have
negatively affected the smoking reduction outcome in this
study. Twelve of the subjects who fulfilled the inclusion
criteria and were randomized at the screening visit had an
expired CO level <10 ppm at the baseline visit, either
because it was an early morning visit or because they had
already reduced smoking. One subject indicated at base-
line that he now smoked less than 15 cpd; at study end,
this subject had failed to quit or reduce smoking. Another
subject, who achieved abstinence (short- and long-term),
had a baseline FTND score of zero but fulfilled the inclu-
sion criteria for cpd and expired CO. The low baseline val-
ues of these subjects did not affect the cessation outcome,
and excluding them from the analyses did not change the
result, although their low baseline CO level made it diffi-
cult for these subjects to fulfill the criteria of reducers.
Previous studies that evaluated the effect of smoking
reduction have recruited smokers who were not willing to
immediately quit, and have also studied only one type of
NRT [5-8]. This is different from a real-life situation where
smokers are exposed to different smoking cessation strat-
egies and NRT is available over-the-counter, and some-
times in self-selection areas of pharmacies or in general
sales, where smokers can choose between different prod-
ucts. This study recruited smokers who were either willing
to quit, or only to reduce their number of cigarettes
smoked per day. They were also exposed to a choice of two
different NRT products. This study is therefore more sim-
ilar to the real life situation and verifies the efficacy of nic-
otine gum and inhaler for smoking cessation when using
individual strategies to reach this goal.
In our trial, both the newspaper ads and subject informa-
tion put equal emphasis on cessation and reduction.
However, recent experience shows that most volunteers
are usually more motivated to quit than to reduce smok-
ing, unless the recruitment procedure is specifically
adapted to enroll "reducers". In a comparable study, spe-
cific inclusion/exclusion criteria to differentiate motiva-
tion to reduce from motivation to quit were successfully
applied [7].
Concurrent use of NRT and smoking is safe, as confirmed
in the present study, and generally does not increase
blood nicotine levels, particularly with nicotine gum or
inhaler [12]. Nor are other biomarkers increased during
smoking reduction while using nicotine inhaler [13]. The
reduction in expired CO in reducers was highly signifi-
cant, even at 12 months, which confirmed the efficacy of
smoking reduction in our subjects.
Current smoking cessation interventions are aimed at
smokers who are already motivated and preparing to quit.
A broader range of interventions is needed in order to
bring more smokers into treatment and increase the num-
bers who are motivated to make quit attempts. In addition
to abrupt cessation, treatment guidelines should recom-
mend NRT-assisted reduction, as a substantial body of evi-
dence shows that gradually cutting down smoking can
increase subsequent smoking cessation among smokers
not currently interested in quitting [4-8,14,15].
Conclusion
In conclusion, NRT (nicotine gum or inhaler) doubled the
quit rate compared to placebo and was safe. Active NRT
achieved sustained abstinence rates of 20.1% at 4 months
and 18.7% at 12 months, which is similar to NRT findings
in studies that enrolled only smokers motivated to quit. In
addition, a large number of smokers managed to reduce
their cigarette consumption by more than 50% compared
to baseline.
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